| Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer B Shankar, J Zhang, AR Naqash, PM Forde, JL Feliciano, KA Marrone, ... JAMA oncology 6 (12), 1952-1956, 2020 | 298 | 2020 |
| Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade CRG Stroud, A Hegde, C Cherry, AR Naqash, N Sharma, S Addepalli, ... Journal of Oncology Pharmacy Practice 25 (3), 551-557, 2019 | 265 | 2019 |
| Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis H Abu-Sbeih, FS Ali, AR Naqash, DH Owen, S Patel, GA Otterson, ... Journal of clinical oncology 37 (30), 2738, 2019 | 166 | 2019 |
| Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease H Abu-Sbeih, DM Faleck, B Ricciuti, RB Mendelsohn, AR Naqash, ... Journal of Clinical Oncology 38 (6), 576, 2020 | 154 | 2020 |
| Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 138 | 2022 |
| Characterization of KRAS mutation subtypes in non–small cell lung cancer J Judd, N Abdel Karim, H Khan, AR Naqash, Y Baca, J Xiu, ... Molecular cancer therapeutics 20 (12), 2577-2584, 2021 | 89 | 2021 |
| Emerging role of immune checkpoint blockade in pancreatic cancer S Macherla, S Laks, AR Naqash, A Bulumulle, E Zervos, M Muzaffar International journal of molecular sciences 19 (11), 3505, 2018 | 87 | 2018 |
| Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 85 | 2021 |
| Considerations for treatment duration in responders to immune checkpoint inhibitors TU Marron, AE Ryan, SM Reddy, S Kaczanowska, RH Younis, D Thakkar, ... Journal for immunotherapy of cancer 9 (3), 2021 | 83 | 2021 |
| Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy P Srivastava, BE Paluch, J Matsuzaki, SR James, G Collamat-Lai, ... Oncotarget 7 (11), 12840, 2016 | 79 | 2016 |
| Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort AR Naqash, B Ricciuti, DH Owen, V Florou, Y Toi, C Cherry, M Hafiz, ... Cancer Immunology, Immunotherapy 69, 1177-1187, 2020 | 73 | 2020 |
| Epigenetics: A primer for clinicians BE Paluch, AR Naqash, Z Brumberger, MJ Nemeth, EA Griffiths Blood reviews 30 (4), 285-295, 2016 | 65 | 2016 |
| Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment J Ansari, AR Naqash, R Munker, H El‐Osta, S Master, JD Cotelingam, ... European journal of haematology 97 (1), 9-16, 2016 | 63 | 2016 |
| Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade DJ Pinato, T Kaneko, A Saeed, T Pressiani, A Kaseb, Y Wang, D Szafron, ... Cancers 12 (7), 1862, 2020 | 57 | 2020 |
| Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study P Fessas, A Kaseb, Y Wang, A Saeed, D Szafron, T Jun, S Dharmapuri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 54 | 2020 |
| Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation … DJ Pinato, TU Marron, PS Mishra-Kalyani, Y Gong, G Wei, D Szafron, ... European Journal of Cancer 157, 140-152, 2021 | 51 | 2021 |
| Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study CAM Fulgenzi, J Cheon, A D'Alessio, N Nishida, C Ang, TU Marron, L Wu, ... European Journal of Cancer 175, 204-213, 2022 | 49 | 2022 |
| The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma A Muhammed, CAM Fulgenzi, S Dharmapuri, M Pinter, L Balcar, ... Cancers 14 (1), 186, 2021 | 46 | 2021 |
| Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS) AR Naqash, GH O’Sullivan Coyne, N Moore, E Sharon, N Takebe, ... J Clin Oncol 39 (15_suppl), 11519, 2021 | 46 | 2021 |
| Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a … AR Naqash, LV Yang, EJ Sanderlin, DC Atwell, PR Walker Acta Oncologica 57 (5), 705-708, 2018 | 45 | 2018 |
